Discordant response of low-density lipoprotein cholesterol and lipoprotein(a) levels to monoclonal antibodies targeting proprotein convertase subtilisin/kexin type 9
Jonathan Edmiston(Oregon Health & Science University), Michael D. Shapiro(Wake Forest University), Nathan A. Brooks(Eli Lilly (United States)), Jessica Minnier(Oregon Health & Science University), Tina M. Kaufman(Oregon Health & Science University), Hagai Tavori(Malmö University), Cezary Wójcik(Oregon Health & Science University), Szilárd Vörös(Piedmont Atlanta Hospital), Bart Duell(Oregon Health & Science University), Sergio Fazio(Regeneron (United States)), Jonathan Q. Purnell(Oregon Health & Science University)
Cited by 41
Related Papers
Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel
|European Heart Journal|2017|3.8k
Low-density lipoproteins cause atherosclerotic cardiovascular disease: pathophysiological, genetic, and therapeutic insights: a consensus statement from the European Atherosclerosis Society Consensus Panel
|European Heart Journal|2020|1.5k
Global burden of metabolic diseases, 1990–2021
|Metabolism|2024|294
Multi-Institution Evaluation of Sequential Gemcitabine and Docetaxel as Rescue Therapy for Nonmuscle Invasive Bladder Cancer
|The Journal of Urology|2019|190
100 years of Bacillus Calmette–Guérin immunotherapy: from cattle to COVID-19
|Nature Reviews Urology|2021|154